Iopamiro (Iopamidol)

Iopamidol contains iodine atoms that strongly absorb X‑ray photons. After intravenous or intra‑arterial injection, the iodine distributes in the vascular and extracellular spaces, increasing the radiodensity of blood vessels and surrounding tissues. This temporary contrast difference makes anatomical details clearer on CT and other radiographic images.

The dose of Iopamiro is individualized by the prescribing clinician based on the specific imaging study, patient body weight, renal function, and the required level of contrast enhancement. No fixed regimen is provided; the healthcare professional calculates the appropriate volume for each procedure.

The safety of Iopamiro in pregnancy and lactation has not been definitively established. It should be used only when clearly needed, after a careful risk‑benefit assessment by the treating physician. Women who are pregnant or breastfeeding should discuss potential risks with their healthcare provider.

To order Iopamiro, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Iopamiro (iopamidol) is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. It provides comparable image quality to other non‑ionic agents such as iohexol or iopromide, while typically causing fewer discomfort‑related reactions and lower risk of nephrotoxicity.

Iopamiro should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze or shake the vial before use.

Iopamiro is administered by a qualified healthcare professional as a sterile solution for injection. It can be given intravenously or intra‑arterially, depending on the imaging procedure, using a power injector or manual bolus technique as directed by the imaging protocol.

The most serious risks include severe allergic reactions such as anaphylaxis, contrast‑induced nephropathy leading to acute kidney injury, and cardiovascular events like severe hypotension or arrhythmias. Immediate medical attention is required if any of these reactions occur during or after administration.

Iopamiro should be avoided in patients with a known hypersensitivity to iopamidol or any iodinated contrast media, those with uncontrolled severe asthma, and individuals with unstable renal function who cannot be adequately hydrated. Clinicians should also exercise caution in patients with thyroid disorders or recent exposure to other iodine‑containing substances.